|

HAVN Life Sciences Update



HAVN Life Sciences Inc. CEO, Tim Moore, updates the recent launch of its new line of natural health products and more.

*To learn more about the company featured in this video and the work they’re doing, visit their website: https://havnlife.com and https://yourhavnlife.com

*Get the latest industry news around all things psychedelics by visiting our website, and be sure to subscribe to our newsletter to never miss a thing.

Subscribe to our YouTube channel: https://bit.ly/3prTiCI
Visit our Website: https://psychedelicspotlight.com
Follow us on Instagram: https://instagram.com/psycspotlight
Like us on Facebook: https://facebook.com/PsychedelicSpotlight
Follow us on Twitter: https://twitter.com/PsycSpotlight

*This interview was recorded on June 16, 2021.

#Natural #Health #News #HAVN #psychedelics

source

Similar Posts

  • Interview with Evan Levine, PsyBio Therapeutics

    In this episode of the Psychedelic Spotlight podcast, we spotlight Evan Levine, Chairman & CEO of PsyBio Therapeutics, an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health issues and other disorders.

  • Can Ketamine Treat Depression? Meet Delic, the LARGEST Ketamine Clinic Company

    In today’s episode, I talk with Matt Stang, CEO of Delic Corp. Delic (OTCMKTS: DELCF) is a psychedelic medicines company aiming to put a dent in the mental health crisis.
    They are doing this in three ways.

    First, through their ketamine clinics. Delic runs the largest ketamine network in the world, with dozens of clinics across North America. At the moment, these clinics are only providing ketamine therapy for disorders like depression, but in the future, once they become legal, Delic also plans on offering other psychedelic therapies such as psilocybin and MDMA therapy.

    Second, through education. Delic runs multiple media platforms, such as RealitySandwich.com. These media platforms aim to educate and entertain, leading towards the destigmatization of psychedelics in our culture. As many of the people behind Delic Corp were behind the legendary High Times Magazine, this is an area of expertise for the company. Ultimately, psychedelic compounds will never succeed as medicines if society does not get behind them. Delic also has podcasts, and they host psychedelic medicine events.

    And third, through science. Delic Labs is currently working on creating next generation psychedelics. Delic Labs also works with third parties, completing research, which allows the labs to run on a profit.

    Taken together, Delic is not only a core player in the psychedelics movement, but they are also one of the companies making a solid revenue.

    Enjoy the episode!
    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Video editing: @themyaholy @Psy_holy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. Psychedelic Spotlight and The Psychedelic Investor were hired for this video, on December 3rd, 2021, to publicly disseminate information about (DELIC CORP) via digital communications. We have been paid ($2000 CAD).

    #Delic #Psychedelics #Ketamine

  • MindMed Financial Results & Business Update Q2 2021 ( Where Does MNMD/MMED Go From Here?)

    MindMed’s Financial Results & Business Update for Q2 2021 are out!
    In this episode, we’ll discuss MindMed, ( MMED: NEO), (MNMD: NASDAQ), (MMQ: FRA), who recently announced their Q2 financials and gave a business update.
    This was an important, transitional quarter for the company for several reasons.

    First, and perhaps most significantly, during Q2, co-founder JR Rahn stepped down as CEO, being replaced by Robert Barrow, who was previously Chief Development Officer.

    Second, in terms of progress in the mission to heal mental health, MindMed made several strides in this quarter, which we’ll discuss today.

    Pertinent links:

    MindMed’s CEO Jr Rahn Steps Down:
    https://thepsychedelicinvestor.com/2021/06/09/mindmed-announces-chief-executive-officer-transition/

    Project Angie Update:
    https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

    MindMed’s Collaboration with NextStage Therapeutics:
    https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/

    MindMed’s Pharmacogenetic Study:
    https://thepsychedelicinvestor.com/2021/05/26/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing/

    MMED’s Q2 Financial Results & Business Update:
    https://thepsychedelicinvestor.com/2021/08/13/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline/

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MindMedStock #MNMD

  • Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn

    In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.

    In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.

    From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.

    Perhaps, psychedelics can treat mental health issues in general.

    Perhaps, ketamine can be used to heal.

    In the conversation, MDMA to treat addiction was also discussed.

    Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.

    With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.

    From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.

    #Psychedelics #Awakn #PsychedelicStocks